Sinovac Biotech ((SVA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinovac Biotech is conducting a clinical trial titled ‘Randomized, Double-blind, Controlled Phase I/II Clinical Trial on the Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Healthy Adults and Children Aged 6 Months to 12 Years.’ The study aims to evaluate the vaccine’s safety and immune response in both adults and children, focusing on adverse events and immunogenicity.
The study tests a tetravalent inactivated enterovirus vaccine, designed to prevent diseases like Hand, Foot, and Mouth Disease and Herpangina. It involves different doses of the vaccine and compares them with a control vaccine and placebo.
This interventional study is randomized with a parallel assignment model and quadruple masking to ensure unbiased results. Its primary goal is prevention, with the study divided into two phases to assess safety and immunogenicity.
Key dates include the study’s start date on December 22, 2024, and the last update on December 31, 2024. These dates mark the initiation of the trial and the most recent information available, respectively.
For investors, this trial could impact Sinovac’s stock performance by potentially enhancing its vaccine portfolio. The study’s progress may influence investor sentiment, especially in the competitive vaccine market.
The study is ongoing, with further details available on the ClinicalTrials portal.